TICKERNERD
Menu
CBIOCBIOHealthcare · Biotechnology

CBIO Stock Forecast: Crescent Biopharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$17
+5.91% on the day

The 8 Wall Street analysts covering Crescent Biopharma, Inc. hold a median 12-month price target of $28 — +62.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$638.5M
Ticker Nerd rank
56 / 100
Median analyst target
$28
Analysts covering
8
Total return, dividends reinvested
1W
+0.3%
1M
+3.3%
YTD
+44.9%
1Y
+19.4%
From 52W high
−36.3%
From 52W low
+92.3%
$9
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Crescent Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
77
Revisions
76
Momentum
57
Accruals
54
Size
51
Quality
46
Volatility
43
Growth
40
Issuance
28

Value (77): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26CBIOHigh $35Median $28Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $27Median $28High $35

The green dot is the last close — the median target sits +62.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
1 June 2026HC Wainwright & Co.DowngradeNeutral—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
21 Jan 2026GuggenheimInitiatesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 Aug 2025JefferiesInitiatesBuy—
11 Aug 2025HC Wainwright & Co.InitiatesBuy—
14 July 2025WedbushInitiatesOutperform—
25 June 2025StifelInitiatesBuy—
18 June 2025LifeSci CapitalInitiatesOutperform$22
15 Nov 2021Raymond JamesDowngradeMarket Perform—
6 Aug 2021Raymond JamesMaintainsOutperform$19 → $18
29 Apr 2021Raymond JamesMaintainsOutperform$18 → $19
10 Feb 2021Piper SandlerInitiatesOverweight—
4 Feb 2021Raymond JamesMaintainsOutperform$20 → $18
4 Jan 2019OppenheimerInitiatesOutperform—
21 June 2018B. Riley FBRDowngradeNeutral—
21 June 2018B. Riley SecuritiesDowngradeNeutral$44 → $13
5 May 2018B. Riley FBRInitiatesBuy—
12 Feb 2018B. Riley SecuritiesMaintainsBuy$19 → $49
9 Feb 2018Chardan CapitalMaintainsBuy$10 → $75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Crescent Biopharma, Inc. (CBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.6×

Cheaper than 69% of US stocks

Price / sales
53.6×

Cheaper than 6% of US stocks

Price / book
3.6×

Cheaper than 30% of US stocks

EV / EBITDA
−3.1×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1432.6%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−75.8%

Higher than 16% of US stocks

Return on assets
−64.1%

Higher than 6% of US stocks

Dividend yield
559.4%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CBIOCrescent Biopharma, Inc.$638.5M
56
SGMTSagimet Biosciences, Inc.$627.1M
31
CRMDCorMedix, Inc.$642.4M
61
MDXGMiMedx Group, Inc.$643.3M
76
SCTXScribe Therapeutics, Inc.$643.8M
1
OABIOmniAb, Inc.$623.3M
93
EIKNEikon Therapeutics, Inc.$616.2M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Crescent Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CBIO news & analysis

Crescent Biopharma Announces Grants of Inducement Awards

GlobeNewsWire · 3 Aug 2026neutral

Crescent Biopharma's Compensation Committee approved on July 31, 2026 the grant of options to purchase 19,425 ordinary shares to one non-executive employee as equity inducement awards under the company's 2025 Inducement Plan, to secure the employee's acceptance of employment.

Why it matters — The inducement grant signals that Crescent is adding staff through equity incentives, which is a routine yet noteworthy detail for shareholders tracking the company's hiring and compensation practices.

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 30 July 2026positive

Crescent Biopharma reported its second quarter 2026 financial results and highlighted progress across its clinical pipeline, including enrollment in the ASCEND Phase 1/2 trial for CR-001 and a new Phase 2 ADC combination study in NSCLC. The company also completed a $143.7 million public offering, extending its expected cash runway into the second half of 2028.

Why it matters — CBIO watchers would care because the update provides clarity on the timeline for multiple key clinical data readouts beginning in Q1 2027, and the public offering extends the company's financial runway, reducing near-term dilution risk.

FAQ

Frequently asked questions about CBIO stock

What is the CBIO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Crescent Biopharma, Inc. have a median 12-month price target of $28, with estimates ranging from $27 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CBIO stock a buy right now?

Of the 8 analysts covering Crescent Biopharma, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Crescent Biopharma, Inc. 56 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CBIO?

As at 22 Aug 2026, Crescent Biopharma, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (77 of 100).

Will CBIO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +62.9% from the last close, and Ticker Nerd's factor model ranks Crescent Biopharma, Inc. 56 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CBIO stock forecast for 2030?

No analyst covering Crescent Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $35 over the next 12 months.

How has CBIO stock performed over the past year?

Crescent Biopharma, Inc. returned +19.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Crescent Biopharma, Inc. do?

Crescent Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies in the pharmaceutical sector.

What is the latest news on CBIO?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Crescent Biopharma Announces Grants of Inducement Awards". Crescent Biopharma's Compensation Committee approved on July 31, 2026 the grant of options to purchase 19,425 ordinary shares to one non-executive employee as equity inducement awards under the company's 2025 Inducement Plan, to secure the employee's acceptance of employment.

Company

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies in the pharmaceutical sector. It specializes in advancing treatments that address significant unmet medical needs, often targeting niche or rare diseases. The company’s pipeline and research efforts aim to bring novel drug candidates through clinical development stages to improve patient outcomes. Crescent Biopharma plays a role in the broader healthcare and life sciences industry by contributing to medical innovation and therapeutic advancements. Its presence in financial markets, including listing on the Frankfurt Stock Exchange, allows investors to track its progress and financial performance as it works toward enhancing treatment options in biomedicine.

CEO Mr. Joshua T. Brumm · 69 employees · United States · https://crescentbiopharma.com